share_log

SpringWorks Therapeutics Has Initiated A Rolling Submission Of A New Drug Application To FDA For Mirdametinib In Pediatric And Adult Patients With Neurofibromatosis Type 1-associated Plexiform Neurofibromas; Expected To Complete By Q2 Of 2024

Benzinga ·  Mar 4 06:37
SpringWorks Therapeutics Has Initiated A Rolling Submission Of A New Drug Application To FDA For Mirdametinib In Pediatric And Adult Patients With Neurofibromatosis Type 1-associated Plexiform Neurofibromas; Expected To Complete By Q2 Of 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment